Incremental cost-effectiveness ratios for primary outcome of mortality and secondary outcome of invasive mechanical ventilation averted (mean cost and effects, per patient) in E-CATCO
| Variable | Cost, Can$ | Deaths averted | ICER |
|---|---|---|---|
| Cost-effectiveness (in-hospital mortality) | |||
| Remdesivir | 37 918.42 | 0.809 | |
| Placebo | 38 026.40 | 0.771 | Remdesivir dominant ($ per death averted) |
| Incremental difference | −$107.98 | 0.038 | |
| Cost-effectiveness (IMV) | |||
| Variable | Cost, Can$ | IMV events averted | ICER |
| Remdesivir | 37 918.42 | 0.836 | |
| Placebo | 38 026.40 | 0.779 | Remdesivir dominant ($ per IMV averted) |
| Incremental difference | −$107.98 | 0.057 | |
Note: CATCO = Canadian Treatments for COVID-19, CI = confidence interval, E-CATCO = economic evaluation alongside CATCO, ICER = incremental cost-effectiveness ratio, IMV = invasive mechanical ventilation.